Cohance Lifesciences Limited has informed the Exchange about change in Management

CEO resignedExternal CEO appointedManagement Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹1001.00

prior close

₹995.45

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.9%-0.8% vs market

Pharmaceuticals peers, median of 149sector+0.8%-0.7% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

+0.1

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+0.9-0.8+0.8-0.7

Next day

-0.5+0.8-1.3+0.9-1.4

-0.6-0.1-0.5+0.0-0.6

-2.0-1.7-0.3-2.1+0.1

-4.2-0.8-3.5-1.4-2.9

-4.8-1.1-3.7-2.0-2.8

-5.9-2.4-3.5-3.3-2.5

15d

-10.6-0.6-10.0-3.1-7.5

-12.6-3.8-8.8-5.2-7.5

-13.2-2.9-10.3-5.7-7.5

-21.6+1.5-23.1-5.1-16.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences has announced a leadership change at its CDMO (Contract Development and Manufacturing) business. Dr. Sudhir Kumar Singh, the current CEO overseeing the CDMO business, has resigned citing health issues and will step down from close of business on July 31, 2025. He will, however, stay on under his existing contract to help with a smooth transition. To fill the role, the company has appointed Mr. Yann D'Herve as the new CEO – CDMO Business, effective August 1, 2025. Yann joins from Evonik, where he most recently served as Senior Vice President and General Manager of the Healthcare division, managing 2,600 employees across 9 manufacturing sites. The change was approved by the Board via circular resolution based on the Nomination and Remuneration Committee's recommendation.

Likely market impact

The change is a like-for-like replacement of the CDMO business head, with an experienced external hire from a global major (Evonik), which should reassure investors. The outgoing CEO's health-related exit appears orderly with a planned handover, reducing execution risk. Near-term stock impact is likely neutral, though the new appointee's global experience could be viewed positively for the CDMO growth strategy.